MiRNA-based therapy for Pulmonary Hypertension (PAH): MiRNA-99 inhibits pulmonary hypertension via induction of PDLIM5, 14/February/2015, 23.22

MiRNA-based therapy for Pulmonary Hypertension (PAH): MiRNA-99 inhibits pulmonary hypertension via induction of PDLIM5, 14/February/2015, 23.22

MiRNA-based therapy for Pulmonary Hypertension (PAH): MiRNA-99 inhibits pulmonary hypertension via induction of PDLIM5, 14/February/2015, 23.22 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that MiRNA-99 may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “MiRNA-99 activators“ may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 300*

Undisclosed information: How miR-99 increases the expression of PDLIM5

To cite: Boominathan, MiRNA-based therapy for Pulmonary Hypertension (PAH): MiRNA-99 inhibits pulmonary hypertension via induction of PDLIM5, 14/February/2015,  23.22,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Share
Start Typing